 Lantern Pharma NASDAQ: LTRN, a clinical stage biotechnology company focused on leveraging artificial intelligence A.I., machine learning and genomic data to streamline the drug development process and to identify the patients that will benefit from its targeted oncology therapies, announced entering into agreements with leading contract manufacturing companies for process development and manufacturing for two of Lanterns oncology drug candidates, LP-300 and LP-184. Lantern Pharma filed an 8-K on Thursday, July 16 describing a recent agreement for GMP manufacturing. 